Kay Roberts
Medical · Palmdale, CANPI 1508057316
Payments from drug & device makers
Across 565 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lilly USA, LLC$1K
- AstraZeneca$983
- GSK$868
- plus $5K from 40 others
What the payments were for
- Food & beverage$11,632100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,643 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $64,434 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $56,135 |
| EliquisApixaban | 60 | $51,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $47,871 |
| JardianceEmpagliflozin | 25 | $44,025 |
| FarxigaDapagliflozin Propanediol | 35 | $35,281 |
| MounjaroTirzepatide | 33 | $34,484 |
| RybelsusSemaglutide | 15 | $24,382 |
| XareltoRivaroxaban | 13 | $21,517 |
| VraylarCariprazine Hcl | 13 | $21,443 |
| EntrestoSacubitril/Valsartan | 19 | $20,888 |
| LinzessLinaclotide | 22 | $18,824 |
| JanuviaSitagliptin Phosphate | 11 | $18,309 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $17,009 |
| Aripiprazole | 44 | $15,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,407 | $88,81659 claims |
| GileadBiktarvy | $143 | $56,13515 claims |
| PfizerEliquis, Dilantin | $201 | $53,32474 claims |
| GSKTrelegy Ellipta | $868 | $47,87146 claims |
| Boehringer IngelheimJardiance | $684 | $44,02525 claims |
| AbbVieVraylar, Linzess, Synthroid | $502 | $43,72381 claims |
| Lilly USA, LLCMounjaro, Humalog | $1,051 | $36,96550 claims |
| AstraZenecaFarxiga | $983 | $35,28135 claims |
| NovartisEntresto | $185 | $20,88819 claims |
| MerckJanuvia | $782 | $18,30911 claims |
| Eisai Inc.Dayvigo | $15 | $4,40113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Palmdale
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.